Although the combination did not significantly improve the survival rate of APL mice compared with those treated with ATRA/arsenic alone (Figure 8J), the PPAR agonist FN synergized with ATRA/arsenic therapy to decrease spleen weights in APL mice (Figure 8K). Here, FN1 is linked to acute promyelocytic leukemia.